March 18, 2020 / 10:18 PM / 14 days ago

BRIEF-Cumberland Pharmaceuticals Reports 17% Revenue Growth For The Full Year 2019

March 18 (Reuters) - Cumberland Pharmaceuticals Inc :

* CUMBERLAND PHARMACEUTICALS REPORTS 17% REVENUE GROWTH FOR THE FULL YEAR 2019

* RECEIVED FDA APPROVAL FOR REDITREX

* CUMBERLAND PHARMACEUTICALS - INITIATED NEW IFETROBAN CLINICAL PROGRAM

* CUMBERLAND PHARMACEUTICALS - QTRLY LOSS PER SHARE $0.06 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below